Wu Ya-Ju, Su Kuei-Ying
Division of Critical Care Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Division of Rheumatology and Immunology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Tzu Chi Med J. 2020 Jul 29;33(1):22-28. doi: 10.4103/tcmj.tcmj_15_20. eCollection 2021 Jan-Mar.
Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disease. The diagnosis of this disease is typically challenging and requires collaboration between clinicians and pathologists. Moreover, it is important to exclude other diseases (such as malignancies, autoimmune diseases, and infectious diseases) that have similar clinical manifestations and pathological findings. Patients with untreated severe MCD have high mortality due to devastating cytokine storms. Thus, early diagnosis and prompt treatment is a key imperative. The diagnosis of MCD is based on the clinical signs of systemic inflammation, serological tests, and typical pathological features. In this review article, we provide an overview of MCD with a focus on the emerging evidence pertaining to its diagnosis and treatment.
多中心Castleman病（MCD）是一种罕见的系统性淋巴增殖性疾病。该疾病的诊断通常具有挑战性，需要临床医生和病理学家之间的协作。此外，排除具有相似临床表现和病理结果的其他疾病（如恶性肿瘤、自身免疫性疾病和感染性疾病）很重要。未经治疗的重度MCD患者由于严重的细胞因子风暴而死亡率很高。因此，早期诊断和及时治疗至关重要。MCD的诊断基于全身炎症的临床体征、血清学检查和典型的病理特征。在这篇综述文章中，我们概述了MCD，重点关注其诊断和治疗方面的新证据。
